Amgen Statement on Briefing Materials Prepared for March 13, 2008 ODAC Meeting

Briefing documents for the March 13th Oncologic Drugs Advisory (ODAC) meeting regarding erythropoiesis-stimulating agents (ESAs) are now available at www.fda.gov.

Amgen strongly believes that ESAs provide an important clinical option for some patients, and looks forward to collaborating with the ODAC and FDA to maximize the benefits of these drugs when used according to the approved labeling while minimizing the risks.

To view the Amgen statement, click here.